Novel targeted therapies in head and neck cancer. - Wikidata - awgldk - TriplyDB

Novel targeted therapies in head and neck cancer.

Novel targeted therapies in head and neck cancer.

http://www.wikidata.org/entity/Q37975224

about

Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.

P2860

Q39433158-2A151FA9-4AA1-4308-9908-EB4AE4F00C93 Q40081751-7C455D52-482B-4F4C-8813-7E1ED1973A26

P2860

Novel targeted therapies in head and neck cancer.

http://www.wikidata.org/entity/Q37975224

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Novel targeted therapies in head and neck cancer.

@en

Novel targeted therapies in head and neck cancer.

@nl

type

label

Novel targeted therapies in head and neck cancer.

@en

Novel targeted therapies in head and neck cancer.

@nl

prefLabel

Novel targeted therapies in head and neck cancer.

@en

Novel targeted therapies in head and neck cancer.

@nl

P1433

Q37975224-C207EABE-0663-4747-AC4C-BD057F390431

P1476

Q37975224-9F6F352E-E867-4021-91FC-E1724277F9C3

P2093

Q37975224-1C10070F-3E46-4006-B075-F881FC9E852D

Q37975224-6D05B846-639E-4D31-B49F-790ACAFA749D

Q37975224-C8460B9D-3FD7-42F9-9326-26B639A06B79

P2860

Q37975224-000DD577-8AAC-4C4D-850B-1FA2DF715BE0

Q37975224-015CA86C-75E4-4E86-BB50-B1A14986CD9C

Q37975224-02508918-AEA8-44FE-A852-2C07D4AE080C

Q37975224-06D622CF-3EBF-4BD6-A654-2D57EE3175CA

Q37975224-06E3EF55-DA5D-4202-86C7-7ABB3DD27836

Q37975224-092219A3-4B75-4413-9E61-C1F24BEEAAEA

Q37975224-0B31DEFB-5668-4DB2-89A9-F6A923B1E1E1

Q37975224-0D89F512-ABB3-4B3E-89A8-39D5B24FC27E

Q37975224-0EB6F15C-85D5-48DC-9227-D70CAC979E10

Q37975224-1022AC17-41E9-49DD-9D89-94E0FE5A87DA

P304

Q37975224-0ABC98DD-BCDD-434D-BD64-6B58F0150F97

P31

Q37975224-3EDEB8F0-A513-41B1-AB36-6D8C489060BC

P356

Q37975224-F64A61CC-429C-492A-9E60-8B7306BA5F24

P407

Q37975224-F907F753-3E8D-43BA-85BF-EBDE09CCFBE7

P433

Q37975224-A4BCCCBE-9816-4D56-921C-8057AC7D93B6

P478

Q37975224-214CB089-FC2F-4B12-9389-DFA05FE1F016

P577

Q37975224-CD89B789-82DA-4F0C-82BE-1E335F19A64A

P5875

Q37975224-5231CD01-951E-4886-BE17-92B534151269

P698

Q37975224-631B9442-267F-4DEA-B5E1-C1CFB8F14903

P356

13543784.2012.651455

P1433

Expert Opinion on Investigational Drugs

P1476

Novel targeted therapies in head and neck cancer.

@en

P2093

Ezra E W Cohen

http://www.w3.org/2001/XMLSchema#string

João Paulo S N Lima

http://www.w3.org/2001/XMLSchema#string

Mariana B A Ferreira

http://www.w3.org/2001/XMLSchema#string

P2860

Structure and functions of the 20S and 26S proteasomes

ErbB receptors: from oncogenes to targeted cancer therapies

The biology of VEGF and its receptors

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

New insights into proteasome function: from archaebacteria to drug development

Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer

How proteolysis drives the cell cycle

Cyclin-dependent kinase pathways as targets for cancer treatment

Cancer cell cycles

A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein

P304

281-295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2012.651455

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221742104

http://www.w3.org/2001/XMLSchema#string

P698

22239178

http://www.w3.org/2001/XMLSchema#string